Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 11, 2016, Pages 6578-6584

  Monogue, Marguerite L ^a   Pettit, Rebecca S ^b   Muhlebach, Marianne ^c   Cies, Jeffrey J ^d   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ACHROMOBACTER XYLOSOXIDANS; ACUTE PULMONARY EXACERBATION; ADULT; ADULT DISEASE; ANTIBIOTIC THERAPY; ARTICLE; BURKHOLDERIA CEPACIA; CHEST TIGHTNESS; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ERYTHEMA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; LIVER FUNCTION TEST; LUNG FIBROSIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SIDE EFFECT; TONGUE SWELLING; VAGINAL PRURITUS; VOLUME OF DISTRIBUTION; ACUTE DISEASE; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MONTE CARLO METHOD; PATIENT SAFETY; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CYSTIC FIBROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PATIENT SAFETY; PENICILLANIC ACID; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 84994494386     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01566-16     Document Type: Article

References (27)

1. Elborn JS. 29 April 2016. Cystic fibrosis. Lancet http://dx.doi.org/10.1016/S0140-6736(16)00576-6.
2. Cystic Fibrosis Foundation. 2014. Patient registry annual data report. Cystic Fibrosis Foundation, Bethesda, MD.
3. Flume P, Mogayzel PJ, Robinson K, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. 2009. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180:802-808. http: //dx.doi.org/10.1164/rccm.200812-1845PP.
4. Touw D. 1998. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 20:149-160. http://dx.doi.org/10.1023/A:1008634911114.
5. Zhanel G, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, III, Karlowsky JA. 2014. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 74:31-51. http://dx.doi.org/10.1007/s40265-013-0168-2.
6. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. 2007. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51:826-830. http://dx.doi.org/10.1128/AAC.00860-06.
7. Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A. 2012. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 56:4771-4778. http://dx.doi.org/10.1128/AAC.00680-12.
8. Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP. 2015. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis 83:53-55. http://dx.doi.org/10.1016/j.diagmicrobio.2015.04.012.
9. Sutherland C, Nicolau DP. 4 April 2016. Development of an HPLC method for the determination of ceftolozane/tazobactam in biological and aqueous matrixes. J Chromatogr Sci http://dx.doi.org/10.1093/chromsci/bmw047.
10. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
11. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Contr 19:716-723. http://dx.doi.org/10.1109/TAC.1974.1100705.
12. Cheymol G. 2000. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39:215-231. http://dx.doi.org/10.2165/00003088-200039030-00004.
13. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. 2005. Quantification of lean bodyweight. Clin Pharmacokinet 44:1051-1065. http://dx.doi.org/10.2165/00003088-200544100-00004.
14. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. 2010. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother 54:3427-3431. http://dx.doi.org/10.1128/AAC.01753-09.
15. Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. 2014. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 58:6311-6314. http://dx.doi.org/10.1128/AAC.03572-14.
16. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. 2010. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:1111-1116. http://dx.doi.org/10.1128/AAC.01183-09.
17. MacVane SH, Kuti JL, Nicolau DP. 2014. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 58:1359-1364. http://dx.doi.org/10.1128/AAC.01463-13.
18. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10. http://dx.doi.org/10.1086/516284.
19. Muller AE, Punt N, Mouton JW. 2013. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68:900-906. http://dx.doi.org/10.1093/jac/dks468.
20. Zamorano L, Juan C, Fernández-Olmos A, Ge Y, Cantón R, Oliver A. 2010. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect 16:1482-1487. http://dx.doi.org/10.1111/j.1469-0691.2010.03130.x.
21. Chandorkar GL, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. 2012. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother 67: 2463-2469. http://dx.doi.org/10.1093/jac/dks246.
22. Chandorkar G, Xiao A, Mouksassi MS, Hershberger E, Krishna G. 2015. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol 55:230-239. http://dx.doi.org/10.1002/jcph.395.
23. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. 2012. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 56:3086-3091. http://dx.doi.org/10.1128/AAC.06349-11.
24. Sörgel F, Kinzig M. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 31: 39-60.
25. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss G, Aitken ML. 2002. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 166:1550-1555. http://dx.doi.org/10.1164/rccm.200202-087OC.
26. Food and Drug Administration. 2014. Zerbaxa® (ceftolozanetazobactam). http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206829lbl.pdf. Accessed 24 June 2016.
27. European Committee on Antimicrobial Susceptibility Testing. 2016. Clinical breakpoints - bacterial (v6.0). http://www.eucast.org/clinical-breakpoints. Accessed 27 May 2016.